Squawk Pod: AI taxes, Dell shares, & A rocket explosion - 05/29/26 | Audio Only

Key Concepts

• AI Token Tax: A proposed fiscal policy to tax the computational usage (tokens) of AI companies to fund federal job programs.
• Oncology Innovation: The strategic shift in pharmaceutical research toward curative treatments for cancer, specifically focusing on earlier intervention and precise therapies.
• Iterative Engineering: The philosophy of viewing technical failures (e.g., rocket explosions) as necessary learning steps in a development cycle.
• GLP-1 Agonists: A class of drugs primarily used for weight loss and diabetes, now being studied for their potential impact on cancer metastasis and surgical procedures.
• Standard of Care: The current medical guidelines for treating specific diseases, which companies like Johnson & Johnson aim to reshape through new clinical data.

---

1. Economic Landscape and Market Performance

The financial markets experienced a strong performance in May, with the S&P 500, Dow, Nasdaq, and Russell 2000 all reaching record levels.

• Performance Metrics: For the month of May, the Dow rose 3.7%, the S&P 500 gained 6%, and the Nasdaq surged 9.1%.
• Oil Prices: A significant decline in crude oil prices (WTI down ~15% for the month) contributed to the positive sentiment in equity markets.
• Dell Technologies: Shares surged following record-breaking revenue growth (88% in the quarter). The company raised its 2027 fiscal year forecast, driven by AI-related infrastructure demand. Dell guided current quarter EPS to $4.80, significantly higher than the $2.98 consensus.

2. Aerospace and Iterative Development

Blue Origin’s New Glenn rocket experienced an explosion during an engine firing test at Cape Canaveral.

• Technical Context: The explosion destroyed part of the launchpad infrastructure, which may delay future testing.
• Perspective: Industry experts and observers frame these events not as catastrophic failures, but as part of an "iterative process" essential for rocket development, drawing parallels to the early challenges faced by SpaceX.

3. Oncology and Pharmaceutical Strategy

Johnson & Johnson (J&J) CEO Wim Duato outlined the company’s ambition to become the world’s leading oncology company by 2030.

• Clinical Focus: J&J is presenting "practice-changing" data at the American Society of Clinical Oncology (ASCO) meeting, specifically regarding localized high-risk prostate cancer. The strategy involves treating patients before and after surgery to reduce recurrence.
• Multiple Myeloma: The company aims to cure the disease by moving precise therapies (bispecific antibodies and cell therapy) into earlier lines of treatment.
• Regulatory Environment: Duato noted that the FDA remains functional and efficient, despite leadership changes, and that J&J has not experienced delays in drug reviews.
• GLP-1 Impact: While GLP-1 drugs have caused a decrease in bariatric surgery procedures, J&J views these as complementary treatments for the morbidly obese. The company is also monitoring research into whether GLP-1s can inhibit cancer metastasis.

4. AI Policy and Labor Protection

House Progressive Caucus Chair Greg Casar proposed a "token tax" on AI companies to mitigate potential mass unemployment caused by automation.

• The Proposal: A tax on "tokens" (a measure of AI compute usage) would fund a federal jobs program modeled after the Great Depression-era Works Progress Administration (WPA).
• Key Arguments:
  • Casar’s Perspective: Without intervention, AI could lead to a "dystopic future" where wealth is concentrated in the hands of a few while millions are displaced. He argues that there is significant "good work" to be done in elder care, childcare, and infrastructure.
  • Counter-Arguments: Critics, including Joe Kernan, argue that taxing AI could slow innovation, potentially ceding a competitive advantage to nations like China.
• Exemptions: Casar suggested that legislation should include exemptions for critical sectors like medical research to ensure rapid development of beneficial AI.

5. Synthesis and Conclusion

The discourse highlights a tension between rapid technological advancement and social stability. While the market celebrates the efficiency gains from AI and the pharmaceutical industry’s "golden era" of innovation, there is a growing political and social debate regarding the "human cost" of these transformations. Whether through J&J’s focus on curing cancer or the proposed AI token tax, the common theme is the necessity of balancing aggressive innovation with regulatory and social frameworks to ensure that progress benefits the broader population.